| Efficacy and safety of natalizumab extended interval dosing BI Yamout, MA Sahraian, N El Ayoubi, H Tamim, J Nicolas, SJ Khoury, ... Multiple sclerosis and related disorders 24, 113-116, 2018 | 65 | 2018 |
| Safety and efficacy of rituximab in multiple sclerosis: a retrospective observational study BI Yamout, NK El-Ayoubi, J Nicolas, Y El Kouzi, SJ Khoury, ... Journal of immunology research 2018, 2018 | 62 | 2018 |
| Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and … G Dbaibo, N El-Ayoubi, S Ghanem, F Hajar, V Bianco, JM Miller, ... Drugs & aging 30, 309-319, 2013 | 42 | 2013 |
| Artificial intelligence extension of the OSCAR‐IB criteria A Petzold, P Albrecht, L Balcer, E Bekkers, AU Brandt, PA Calabresi, ... Annals of clinical and translational neurology 8 (7), 1528-1542, 2021 | 36 | 2021 |
| Risk of relapses during pregnancy among multiple sclerosis patients R Alroughani, S Akhtar, M Zeineddine, YEL Kouzi, NK El Ayoubi, ... Multiple Sclerosis and Related Disorders 34, 9-13, 2019 | 24 | 2019 |
| Retinal measures correlate with cognitive and physical disability in early multiple sclerosis NK El Ayoubi, S Ghassan, M Said, J Allam, H Darwish, SJ Khoury Journal of neurology 263, 2287-2295, 2016 | 24 | 2016 |
| Risk factors for incident symptomatic knee osteoarthritis: A population‐based case control study in Lebanon N El Ayoubi, M Chaaya, Z Mahfoud, RR Habib, I Uthman, ZN Slim International journal of rheumatic diseases 16 (2), 211-218, 2013 | 22 | 2013 |
| Blood biomarkers as outcome measures in inflammatory neurologic diseases NK El Ayoubi, SJ Khoury Neurotherapeutics 14 (1), 135-147, 2017 | 19 | 2017 |
| Effect of vitamin D replacement on immunological biomarkers in patients with multiple sclerosis MF Mrad, NK El Ayoubi, MO Esmerian, JM Kazan, SJ Khoury Clinical Immunology 181, 9-15, 2017 | 18 | 2017 |
| Epidemiology of multiple sclerosis in Lebanon: A rising prevalence in the middle east M Zeineddine, A Al Hajje, A Hussein, N El Ayoubi, B Yamout Multiple Sclerosis and Related Disorders 52, 102963, 2021 | 15 | 2021 |
| Effect of fingolimod vs interferon treatment on OCT measurements and cognitive function in RRMS NK El Ayoubi, SWB Reslan, MM Baalbaki, H Darwish, SJ Khoury Multiple Sclerosis and Related Disorders 53, 103041, 2021 | 10 | 2021 |
| Serum vitamin D level is associated with speed of processing in multiple sclerosis patients H Darwish, N Farran, S Hannoun, N Tadros, B Yamout, NK El Ayoubi, ... The Journal of Steroid Biochemistry and Molecular Biology 200, 105628, 2020 | 10 | 2020 |
| Gadolinium effect on thalamus and whole brain tissue segmentation S Hannoun, M Baalbaki, R Haddad, S Saaybi, NK El Ayoubi, BI Yamout, ... Neuroradiology 60, 1167-1173, 2018 | 10 | 2018 |
| Gadoterate meglumine administration in multiple sclerosis has no effect on the dentate nucleus and the globus pallidus signal intensities S Hannoun, R Issa, NK El Ayoubi, R Haddad, M Baalbaki, BI Yamout, ... Academic Radiology 26 (10), e284-e291, 2019 | 6 | 2019 |
| Acute neurological visual loss in young adults: causes, diagnosis and management R Sawaya, N El Ayoubi, R Hamam Postgraduate medical journal 91 (1082), 698-703, 2015 | 5 | 2015 |
| Toxocara infection in the differential diagnosis of multiple sclerosis in the Middle East M Baalbaki, M El Najjar, S Atweh, NK El Ayoubi Multiple Sclerosis Journal–Experimental, Translational and Clinical 6 (1 …, 2020 | 4 | 2020 |
| Clinical validation of a multi-protein, Serum-based assay for disease activity assessments in multiple sclerosis T Chitnis, J Foley, C Ionete, NK El Ayoubi, S Saxena, P Gaitan-Walsh, ... Clinical Immunology 253, 109688, 2023 | 3 | 2023 |
| Challenges to longitudinal characterization of lower urinary tract dysfunction in multiple sclerosis TB Kaplan, A Gopal, VJ Block, AM Suskind, C Zhao, M Polgar-Turcsanyi, ... Multiple Sclerosis and Related Disorders 62, 103793, 2022 | 3 | 2022 |
| Clinical validation study results of a multivariate proteomic serum based assay for disease activity assessments in multiple sclerosis T Chitnis, J Foley, C Ionete, N El Ayoubi, S Saxena, P Gaitan-Walsh, ... Age (Mean±SD) 41 (12.7), 42.5-13.5, 2021 | 3 | 2021 |
| Current and future trends in multiple sclerosis management: Near East perspective A Hatem, NK El Ayoubi, M Habahbeh, Z Ghanim, M Al-Naqshbandi, ... Multiple Sclerosis and Related Disorders, 104800, 2023 | 2 | 2023 |
